Online inquiry

IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2532MR)

This product GTTS-WQ2532MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2532MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4872MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ169MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ9976MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ6904MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ12773MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ11277MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ6595MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6235MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW